FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2991655858> ?p ?o ?g. }

• W2991655858 abstract "Abstract Objectives This study sought to investigate the clinical outcomes of patients with and without peripheral artery disease (PAD) in the BRAVO‐3 trial with respect to the effect of bivalirudin versus unfractionated heparin (UFH). Background PAD is found frequently in patients undergoing transcatheter aortic valve replacement (TAVR) and is reported to confer an increased risk of adverse events. It is unknown whether patients with and without PAD may demonstrate a differential response to bivalirudin versus UFH. Methods BRAVO‐3 was a randomized multicenter trial comparing transfemoral TAVR with bivalirudin versus UFH (31 centers, n = 802). Major adverse cardiovascular events (MACE) were a composite of 30‐day death, myocardial infarction, or cerebrovascular accidents (CVA). Net adverse cardiovascular events (NACE) were a composite of major bleeding or MACE. Results The total cohort included 119 patients with PAD. Vascular complications occurred significantly more frequently in patients with PAD both in‐hospital (25.2 vs. 16.7%; OR 1.68) and at 30 days (29.4 vs. 17.3%; OR 1.99). No significant differences were observed regarding mortality, NACE, MACE, major bleeding or CVA with bivalirudin versus UFH among patients with or without PAD. In patients with PAD, bivalirudin was associated with an increased risk of minor vascular complications at 30 days. Conclusions Patients with PAD undergoing transfemoral TAVR did not exhibit an increased risk of any major adverse events, according to the procedural anticoagulant randomization. However, patients treated with Bivalirudin had significantly higher rates of minor vascular complications." @default.
• W2991655858 created "2019-12-13" @default.
• W2991655858 creator A5000135844 @default.
• W2991655858 creator A5003272933 @default.
• W2991655858 creator A5003293616 @default.
• W2991655858 creator A5003432010 @default.
• W2991655858 creator A5003885355 @default.
• W2991655858 creator A5007123733 @default.
• W2991655858 creator A5008714150 @default.
• W2991655858 creator A5016139987 @default.
• W2991655858 creator A5017722452 @default.
• W2991655858 creator A5017726365 @default.
• W2991655858 creator A5022176990 @default.
• W2991655858 creator A5026908997 @default.
• W2991655858 creator A5034537373 @default.
• W2991655858 creator A5042700458 @default.
• W2991655858 creator A5042959417 @default.
• W2991655858 creator A5045450571 @default.
• W2991655858 creator A5045650183 @default.
• W2991655858 creator A5056423254 @default.
• W2991655858 creator A5056506041 @default.
• W2991655858 creator A5065347832 @default.
• W2991655858 creator A5065991559 @default.
• W2991655858 date "2019-12-05" @default.
• W2991655858 modified "2023-10-14" @default.
• W2991655858 title "Clinical outcomes after TAVR with heparin or bivalirudin as periprocedural anticoagulation in patients with and without peripheral arterial disease: Results from the BRAVO‐3 randomized trial" @default.
• W2991655858 cites W1702536112 @default.
• W2991655858 cites W1989586445 @default.
• W2991655858 cites W2001177205 @default.
• W2991655858 cites W2067905792 @default.
• W2991655858 cites W2071703262 @default.
• W2991655858 cites W2073159589 @default.
• W2991655858 cites W2084685388 @default.
• W2991655858 cites W2100485010 @default.
• W2991655858 cites W2121947900 @default.
• W2991655858 cites W2122694177 @default.
• W2991655858 cites W2122891093 @default.
• W2991655858 cites W2136304981 @default.
• W2991655858 cites W2143349941 @default.
• W2991655858 cites W2149609916 @default.
• W2991655858 cites W2156927593 @default.
• W2991655858 cites W2164686231 @default.
• W2991655858 cites W2165613421 @default.
• W2991655858 cites W2166180650 @default.
• W2991655858 cites W2201168640 @default.
• W2991655858 cites W2324073140 @default.
• W2991655858 cites W2379168276 @default.
• W2991655858 cites W2766584416 @default.
• W2991655858 cites W2781247464 @default.
• W2991655858 cites W2921388585 @default.
• W2991655858 cites W2922215374 @default.
• W2991655858 doi "https://doi.org/10.1002/ccd.28642" @default.
• W2991655858 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7540270" @default.
• W2991655858 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31808295" @default.
• W2991655858 hasPublicationYear "2019" @default.
• W2991655858 type Work @default.
• W2991655858 sameAs 2991655858 @default.
• W2991655858 citedByCount "4" @default.
• W2991655858 countsByYear W29916558582020 @default.
• W2991655858 countsByYear W29916558582021 @default.
• W2991655858 countsByYear W29916558582022 @default.
• W2991655858 crossrefType "journal-article" @default.
• W2991655858 hasAuthorship W2991655858A5000135844 @default.
• W2991655858 hasAuthorship W2991655858A5003272933 @default.
• W2991655858 hasAuthorship W2991655858A5003293616 @default.
• W2991655858 hasAuthorship W2991655858A5003432010 @default.
• W2991655858 hasAuthorship W2991655858A5003885355 @default.
• W2991655858 hasAuthorship W2991655858A5007123733 @default.
• W2991655858 hasAuthorship W2991655858A5008714150 @default.
• W2991655858 hasAuthorship W2991655858A5016139987 @default.
• W2991655858 hasAuthorship W2991655858A5017722452 @default.
• W2991655858 hasAuthorship W2991655858A5017726365 @default.
• W2991655858 hasAuthorship W2991655858A5022176990 @default.
• W2991655858 hasAuthorship W2991655858A5026908997 @default.
• W2991655858 hasAuthorship W2991655858A5034537373 @default.
• W2991655858 hasAuthorship W2991655858A5042700458 @default.
• W2991655858 hasAuthorship W2991655858A5042959417 @default.
• W2991655858 hasAuthorship W2991655858A5045450571 @default.
• W2991655858 hasAuthorship W2991655858A5045650183 @default.
• W2991655858 hasAuthorship W2991655858A5056423254 @default.
• W2991655858 hasAuthorship W2991655858A5056506041 @default.
• W2991655858 hasAuthorship W2991655858A5065347832 @default.
• W2991655858 hasAuthorship W2991655858A5065991559 @default.
• W2991655858 hasBestOaLocation W29916558581 @default.
• W2991655858 hasConcept C126322002 @default.
• W2991655858 hasConcept C141071460 @default.
• W2991655858 hasConcept C164705383 @default.
• W2991655858 hasConcept C168563851 @default.
• W2991655858 hasConcept C197934379 @default.
• W2991655858 hasConcept C2777557582 @default.
• W2991655858 hasConcept C2777565915 @default.
• W2991655858 hasConcept C2778205648 @default.
• W2991655858 hasConcept C2778213512 @default.
• W2991655858 hasConcept C2780007028 @default.
• W2991655858 hasConcept C2780026749 @default.
• W2991655858 hasConcept C2780400711 @default.
• W2991655858 hasConcept C2780739214 @default.
• W2991655858 hasConcept C500558357 @default.
• W2991655858 hasConcept C71924100 @default.
• W2991655858 hasConceptScore W2991655858C126322002 @default.

• next